View Future Growthco.don 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 co.don 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Biotechs 산업 성장률-14.59%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Sep 2024최근 과거 실적 업데이트공시 • Apr 20co.don AG to Report Q4, 2025 Results on Apr 21, 2026co.don AG announced that they will report Q4, 2025 results on Apr 21, 2026공시 • Apr 15co.don AG to Report Q4, 2025 Results on Apr 14, 2026co.don AG announced that they will report Q4, 2025 results on Apr 14, 2026공시 • Mar 10co.don AG to Report Q2, 2025 Results on Mar 10, 2026co.don AG announced that they will report Q2, 2025 results on Mar 10, 2026공시 • Feb 25co.don AG to Report Fiscal Year 2025 Results on Feb 24, 2026co.don AG announced that they will report fiscal year 2025 results on Feb 24, 2026Reported Earnings • Jul 12Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.1%. Over the next year, revenue is forecast to grow 66%, compared to a 28% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.모든 업데이트 보기Recent updates공시 • Apr 20co.don AG to Report Q4, 2025 Results on Apr 21, 2026co.don AG announced that they will report Q4, 2025 results on Apr 21, 2026공시 • Apr 15co.don AG to Report Q4, 2025 Results on Apr 14, 2026co.don AG announced that they will report Q4, 2025 results on Apr 14, 2026공시 • Mar 10co.don AG to Report Q2, 2025 Results on Mar 10, 2026co.don AG announced that they will report Q2, 2025 results on Mar 10, 2026공시 • Feb 25co.don AG to Report Fiscal Year 2025 Results on Feb 24, 2026co.don AG announced that they will report fiscal year 2025 results on Feb 24, 2026New Risk • Oct 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Market cap is less than US$10m (€657.4k market cap, or US$695.0k).공시 • Jan 26ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW).ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023.Breakeven Date Change • Nov 30Forecast to breakeven in 2023The analyst covering co.don expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Average annual earnings growth of 114% is required to achieve expected profit on schedule.Price Target Changed • Nov 17Price target decreased to €6.30Down from €7.60, the current price target is provided by 1 analyst. New target price is 31,088% above last closing price of €0.02. Stock is down 99% over the past year. The company is forecast to post a net loss per share of €0.20 next year compared to a net loss per share of €0.41 last year.Reported Earnings • Jul 12Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.1%. Over the next year, revenue is forecast to grow 66%, compared to a 28% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 335% above last closing price of €1.35. Stock is down 23% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.Price Target Changed • Feb 01Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 252% above last closing price of €1.66. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.Price Target Changed • Jun 22Price target increased to €4.20Up from €3.80, the current price target is an average from 2 analysts. New target price is 200% above last closing price of €1.40. Stock is up 13% over the past year.Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Nov 20New 90-day high: €1.56The company is up 30% from its price of €1.20 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.41 per share.Is New 90 Day High Low • Oct 13New 90-day low: €0.93The company is down 28% from its price of €1.30 on 15 July 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.53 per share.Is New 90 Day High Low • Sep 25New 90-day low: €0.99The company is down 36% from its price of €1.54 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.52 per share.매출 및 비용 세부 내역co.don가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:CNW 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Sep 24000030 Jun 242-10030 Sep 23602030 Sep 226-1711030 Jun 2210-1411031 Mar 2210-1211031 Dec 2110-911030 Sep 218-1011030 Jun 217-1110031 Mar 216-1310031 Dec 206-1410030 Sep 206-1511030 Jun 207-1611031 Mar 207-1410031 Dec 197-1310030 Sep 196-119030 Jun 196-98031 Mar 196-78031 Dec 186-68030 Sep 186-78030 Jun 186-88031 Mar 186-87031 Dec 176-77030 Sep 176-66030 Jun 176-56031 Mar 176-45031 Dec 166-45030 Sep 166-35030 Jun 166-35031 Mar 165-34031 Dec 155-34030 Sep 155-24030 Jun 155-240양질의 수익: CNW가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 CNW의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 CNW의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: CNW의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: CNW의 지난 해 수익 증가율이 Biotechs 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: CNW는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 01:15종가2026/05/22 00:00수익2024/09/30연간 수익2024/09/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스co.don AG는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Peter-Thilo HaslerSphene Capital GmbHUlrich HuwaldWarburg Research GmbHHarald HofWarburg Research GmbH
공시 • Apr 20co.don AG to Report Q4, 2025 Results on Apr 21, 2026co.don AG announced that they will report Q4, 2025 results on Apr 21, 2026
공시 • Apr 15co.don AG to Report Q4, 2025 Results on Apr 14, 2026co.don AG announced that they will report Q4, 2025 results on Apr 14, 2026
공시 • Mar 10co.don AG to Report Q2, 2025 Results on Mar 10, 2026co.don AG announced that they will report Q2, 2025 results on Mar 10, 2026
공시 • Feb 25co.don AG to Report Fiscal Year 2025 Results on Feb 24, 2026co.don AG announced that they will report fiscal year 2025 results on Feb 24, 2026
Reported Earnings • Jul 12Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.1%. Over the next year, revenue is forecast to grow 66%, compared to a 28% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
공시 • Apr 20co.don AG to Report Q4, 2025 Results on Apr 21, 2026co.don AG announced that they will report Q4, 2025 results on Apr 21, 2026
공시 • Apr 15co.don AG to Report Q4, 2025 Results on Apr 14, 2026co.don AG announced that they will report Q4, 2025 results on Apr 14, 2026
공시 • Mar 10co.don AG to Report Q2, 2025 Results on Mar 10, 2026co.don AG announced that they will report Q2, 2025 results on Mar 10, 2026
공시 • Feb 25co.don AG to Report Fiscal Year 2025 Results on Feb 24, 2026co.don AG announced that they will report fiscal year 2025 results on Feb 24, 2026
New Risk • Oct 01New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2022 fiscal period end). Market cap is less than US$10m (€657.4k market cap, or US$695.0k).
공시 • Jan 26ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW).ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023.
Breakeven Date Change • Nov 30Forecast to breakeven in 2023The analyst covering co.don expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2023. Average annual earnings growth of 114% is required to achieve expected profit on schedule.
Price Target Changed • Nov 17Price target decreased to €6.30Down from €7.60, the current price target is provided by 1 analyst. New target price is 31,088% above last closing price of €0.02. Stock is down 99% over the past year. The company is forecast to post a net loss per share of €0.20 next year compared to a net loss per share of €0.41 last year.
Reported Earnings • Jul 12Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.1%. Over the next year, revenue is forecast to grow 66%, compared to a 28% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 335% above last closing price of €1.35. Stock is down 23% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.
Price Target Changed • Feb 01Price target decreased to €5.85Down from €7.60, the current price target is an average from 2 analysts. New target price is 252% above last closing price of €1.66. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year.
Price Target Changed • Jun 22Price target increased to €4.20Up from €3.80, the current price target is an average from 2 analysts. New target price is 200% above last closing price of €1.40. Stock is up 13% over the past year.
Reported Earnings • May 06Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019)The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Nov 20New 90-day high: €1.56The company is up 30% from its price of €1.20 on 21 August 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.41 per share.
Is New 90 Day High Low • Oct 13New 90-day low: €0.93The company is down 28% from its price of €1.30 on 15 July 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.53 per share.
Is New 90 Day High Low • Sep 25New 90-day low: €0.99The company is down 36% from its price of €1.54 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.52 per share.